Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	4.03B +64.3%
Revenue (ttm)	7.70M +640.7%
Net Income	-465.32M
EPS	-4.95
Shares Out	104.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	658,354
Open	39.03
Previous Close	39.10
Day's Range	38.09 - 39.47
52-Week Range	25.83 - 57.99
Beta	0.31
Analysts	Strong Buy
Price Target	76.63 (+98.99%)
Earnings Date	May 7, 2026

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2018
• Employees: 594
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX
• Website: https://www.crinetics.com

Financial Performance

In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.

Analyst Summary

According to 8 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price target is $76.63, which is an increase of 98.99% from the latest price.

Price Target

$76.63

(98.99% upside)

Analyst Consensus: Strong Buy